Gene Therapy PipelineThe company’s broader gene therapy pipeline could provide additional upside potential.
Regulatory ProgressSLDB plans to initiate a separate randomized, double-blind, placebo-controlled study of SGT-003 to support potential global regulatory submissions.
Safety ProfileSGT-003 continues to be well-tolerated with no treatment-emergent serious adverse events, indicating a strong safety profile.